Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.

By A. Lujambio, S. Ropero, Esteban Ballestar, M. Fraga, Celia Cerrato, F. Setién, Sara Casado, A. Suárez-Gauthier, M. Sanchez-Cespedes, Anna Git and 5 more. Cancer Research, 2007

975 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1268e9560ee1a71cc3675722fe3f27dc05b0f880

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

microRNAs in cancer (2013, background): “Similarly, the hypermethylation of miR-124a in colon cancer allows the upregulation of the oncogene CDK6 kinase (89).”
MicroRNAs in cancer: small molecules with a huge impact. (2009, background): “A different approach to identifying epigenetically regulated microRNAs was represented by the microRNA profiling of DNMT1- and DNMT3b-deficient colorectal cancer cells: among the 18 microRNAs upmodulated in comparison with wild-type cells, the only one resulting unmethylated in normal tissue but hyp”
Targeting MicroRNAs in Cancer: Rationale, Strategies and Challenges (2010, neutral): “In addition to structural genetic alterations, the silencing of structurally normal miRNA genes by DNA promoter hypermethylation and/or histone hypoacetylation has been described in solid tumours and in haematological malignancie”
Genomic profiling of microRNA and mRNA reveals deregulated microRNA expression in prostate cancer (2008, background): “<7 (5–6) 15 (25) 8 (27) 7 (23) z7 (7–9) 45 (75) 22 (73) 23 (77) 1.”
Genetic variants of miRNA sequences and non-small cell lung cancer survival. (2008, background): “The precise mechanisms regulating miRNA expression and maturation are largely unknown, but studies have suggested several mechanisms, including genetic and epigenetic alterations (11, 12).”
MicroRNA signatures in human ovarian cancer. (2007, background): “More recently, few evidences have shown that miRNA genes may be regulated also by epigenetic mechanisms, as changes in genomic DNA methylation pattern: miR-127 (25) and miR-124a (26) are transcriptionally inactivated by CpG island hypermethylation, whereas in lung cancer, the overexpression of let-7”
DNA methylation and cancer. (2010, background): “As a consequence, RB protein, a tumorsuppressor gene, crucial in cell-cycle regulation, may be inactivated by CDK6mediated phosphorylation (Lujambio et al., 2007).”
miRecords: an integrated resource for microRNA–target interactions (2008, methodology): “The methods commonly applied to over- or misexpress miRNAs include mature miRNA transfection (38), miRNA precursor transfection (39) and indirectly induced miRNA overexpression [using the DNA demethylatingn agent 5-AzaDeoxycytidine (40), or the histone deacetylase inhibitor phenylbutyrate (PBA) (41)”
Non-coding RNAs in human disease (2011, background): “These compounds release the epigenetic silencing of tumour suppressor ncRNAs, as has been shown for miRNAs and T-UCRs, thereby stopping tumoural growth and ultimately resulting in the programmed cell death of the transformed cell”
Epigenetic gene silencing in cancer: the DNA hypermethylome. (2007, background): “Second, using a genetic approach that takes advantage of the genomic disruption of DNMT1 and DNMT3b in cancer cells, we have demonstrated that CpG island hypermethylation is a mechanism that can account for the downregulation of miRNAs in human cancer (12).”
Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. (2008, background): “CDK6 regulates major cell cycle transitions as an oncogene and has been reported the potential target of miR-124a , which is epigenetically silenced in human cancers (11).”
microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer (2011, background): “The mechanisms by which ncRNA expression is altered in cancers are similar to those for protein coding genes, and include epigenetic mechanisms (Lujambio et al., 2007, 2008; Saito et al., 2010).”
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome (2011, background): “As an additional internal control, the 450K microarray also detected the loss of promoter CpG island hypermethylation of the previously reported hypermethylated tumor suppressor coding genes in DKO cells(29-32,34) and non-coding RNAs.(33,35) Interestingly, there were 191,000 (74.”